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NAD+ is essential for redox reactions in energy meta-
bolism and necessary for DNA repair and epigenetic
modification. Humans require sufficient amounts of
dietary niacin (nicotinic acid, nicotinamide, and nico-
tinamide riboside) for adequate NAD+ synthesis. In
contrast, mice easily generate sufficient NAD+ solely
from tryptophan through the kynurenine pathway.
We show that transgenic mice with inducible
expression of human alpha-amino-beta-carboxy-
muconate-semialdehyde decarboxylase (ACMSD)
become niacin dependent similar to humans when
ACMSD expression is high. On niacin-free diets,
these acquired niacin dependency (ANDY) mice
developed reversible, mild-to-severe NAD+ defi-
ciency, depending on the nutrient composition of
the diet. NAD deficiency in mice contributed to
behavioral and health changes that are reminiscent
of human niacin deficiency. This study shows that
ACMSD is a key regulator of mammalian dietary
niacin requirements and NAD+ metabolism and that
the ANDY mouse represents a versatile platform for
investigating pathologies linked to low NAD+ levels
in aging and neurodegenerative diseases.INTRODUCTION
Humans depend on B3 vitamins (nicotinic acid and nicotin-
amide), nicotinamide riboside, and tryptophan as dietary precur-
sors for nicotinamide adenine dinucleotide (NAD+) synthesis
(Kirkland and Meyer-Ficca, 2018). NAD+ levels in whole bloodCell Re
This is an open access article undcan be measured to assess adequate dietary niacin intake (Fu
et al., 1989; Jacobson et al., 1999; Tang et al., 2008). NAD+ levels
vary significantly between individuals, and up to 15%–20% of
the general population and 26% of elderly people may be niacin
deficient, even in countries with niacin-fortification programs
(Jacobson, 1993; Paulionis et al., 2005). Such NAD+ deficiency
is often not clinically recognized or understood, but potentially
highly prevalent and therefore a current research focus. Particu-
larly aging-associatedmetabolic changes are linked to lowNAD+
levels (Imai, 2009, 2011; Imai and Guarente, 2014; Rehan et al.,
2014). NAD+ and the reduced form NADH are coenzymes for
redox reactions in metabolic processes such as the Krebs cycle,
glycolysis, fatty acid oxidation, gluconeogenesis, and lipid and
steroid synthesis. NAD+ is also a co-substrate for sirtuins, which
are epigenetic regulators, and ADP-ribose transferases. Sirtuins
are class III NAD+-dependent histone deacetylases that regulate
metabolic function, longevity, and aging (Imai and Guarente,
2016; O’Callaghan and Vassilopoulos, 2017). Availability and
redox status of NAD+ are emerging as major factors in the devel-
opment of disorders, including metabolic dysfunction linked to
aging-related pathophysiology of the circadian rhythm, DNA
repair, and cancer (Asher and Sassone-Corsi, 2015; Belden
and Dunlap, 2008; Imai, 2010). Variations in NAD+ levels may
therefore link the metabolic status of a cell to its epigenetic reg-
ulatory machinery. The ‘‘NAD World’’ describes this concept
(Imai, 2009, 2010, 2016; Imai and Guarente, 2016).
Modeling NAD+ deficiency in rodents has been problematic
because they efficiently convert tryptophan to NAD+ via the
kynurenine pathway (Figure 1) and do not seem to depend as
much on dietary niacin as a precursor for NAD+ synthesis as hu-
mans. Humans need 60–70 mg of tryptophan to produce the
equivalent of the amount of NAD+ produced from 1 mg of niacin,
if consuming an experimental diet that is tryptophan rich and
niacin-free (Fukuwatari et al., 2004; Horwitt et al., 1981). With
limited dietary tryptophan, this conversion rate is even lowerports 25, 1359–1370, October 30, 2018 ª 2018 The Authors. 1359



































Figure 1. The Principle Underlying Acquired
Niacin Dependency by Overexpression of
ACMSD
In addition to its relevance for serotonin, melatonin,
tryptamine, and general protein synthesis, dietary
tryptophan can be converted to either NAD+ or
acetyl-CoA via the kynurenine metabolic pathway
in mammals. ACMSD, ACMS decarboxylase
[EC:4.1.1.45]; AFMID, N-formylkynurenine for-
mamidase [EC:3.5.1.9]; CoA, coenzyme A;
HAAO, 3-hydroxyanthranilate 3,4-dioxygenase
[EC:1.13.11.6]; IDO1, indoleamine 2,3-dioxyge-
nase 1 [EC:1.13.11.52]; IDO2, indoleamine 2,3-di-
oxygenase 2 [EC:1.13.11.52]; KMO, kynurenine
3-monooxygenase [EC:1.14.13.9]; KYNU, kynur-
eninase [EC:3.7.1.3]; NAD+, nicotinamide adenine
dinucleotide; NMNAT, nicotinamide mono-
nucleotide adenylyltransferase [EC:2.7.7.1 2.7.7.18];
QPRT, quinolinate phosphoribosyl transferase
[EC:2.4.2.19]; TCA cycle, tricarboxylic acid cycle;
TDO, tryptophan 2,3-dioxygenase [EC:1.13.11.11].(Fu et al., 1989). This relatively inefficient tryptophan-to-
NAD+ conversion rate, when compared to the conversion
rate in rodents, makes humans susceptible to developing
NAD+ deficiency on niacin-free and protein-poor diets. Several
knockout mouse models have been generated to disrupt the
kynurenine pathway, but these mice either did not become
truly NAD+ deficient due to enzyme redundancy or the disrup-
tions caused the accumulation of toxic intermediates (Terakata
et al., 2012, 2013). Considering alternative strategies, we hy-
pothesized that the differences in rodent and human niacin re-1360 Cell Reports 25, 1359–1370, October 30, 2018quirements may be caused by the different
efficiency of a key enzymatic step in
the de novo NAD+ synthesis from trypto-
phan in the kynurenine pathway. In this
step, the intermediate tryptophan metabo-
lite alpha-amino-beta-carboxy-muconate-
semialdehyde (ACMS) is either decarboxy-
lated by the enzyme ACMS decarboxylase
(ACMSD) to alpha-amino-muconate-semi-
aldehyde (AMS) or left to undergo sponta-
neous cyclization to form quinolinic acid.
Quinolinic acid then serves as a precursor
for NAD+ synthesis, whereas AMS sponta-
neously forms picolinic acid, which is ulti-
mately metabolized to acetyl coenzyme A
(acetyl-CoA). The efficiency of NAD+ syn-
thesis from tryptophan should therefore
hinge on the extent of ACMS accumula-
tion, which is regulated by ACMSD. Low
ACMSD activity should permit efficient
NAD+ synthesis from tryptophan, while
high ACMSD activity is expected to pre-
vent efficient tryptophan-to-NAD+ conver-
sion. The formation of quinolinate and
NAD+ is impaired if there is high activity
of ACMSD, and this appears to be a main
source of variation between species inthe efficiency of the conversion of tryptophan to NAD+ (Ikeda
et al., 1965)
If ACMSD is the gatekeeper that shunts tryptophan to either
NAD+ or acetyl-CoA synthesis, then high ACMSD activity should
result in the dependence of an individual on dietary niacin as a
source of NAD+, which could be the case in niacin-dependent
species such as humans. We generated a transgenic mouse
model with inducible human (h)ACMSD overexpression (ac-
quired niacin deficiency, or ANDY, mouse) to test the hypothesis
























































































































Figure 2. Doxycycline-Inducible Expression
of hACMSD Results in Dietary Niacin-
Dependent Decrease in NAD+ and NADP+
Levels
(A) ACMSD overexpression remained stable for at
least 4 months. Immunoblot analysis of hACMSD
expression in liver from male transgenic ANDY
littermates after 4 months on defined diets and
continuous DOX administration. Different niacin
content in feed did not affect transgene expres-
sion. Alpha-tubulin served as loading control.
(B) Design of feeding trials. DOX administration
induced hACMSD transgene expression (Dox);
animals without ACMSD expression were controls
(water). Within each group, equal numbers of mice
were assigned to a niacin-depleted diet (ND1),
a niacin-replete but otherwise identical diet
(CD1), or chow feed (chow; diet compositions in
Tables S1 and S2).
(C and D) Reduced blood NAD+ inmale ANDYmice
after 3 weeks (C) and 12 weeks (D) on niacin-free
diet (ND1) compared to controls without hACMSD
overexpression or on niacin-replete feed (CD1,
chow). Data on ANDY/DOX/ND1 and ANDY/DOX/
CD1 mice are from 4 and 3 independent experi-
ments in (C) and (D), respectively. All dataata
represent mean ± SEM.
(E) Lower NAD+ levels in ANDYmice after 10weeks
on ND1 in all tissues tested. NADP+ levels were
also lower, with significant differences only seen
in blood, liver, and brain. Dots represent individual
mice in (C)–(E): red dots are ANDY/Dox/
ND1, blue dots are ANDY/DOX/CD1. One-way
ANOVA, Tukey’s multiple comparison test. All data
represent mean ± SD.
**p < 0.01, ***p < 0.001.
See also Figures S1, S2, and S3.which should result in NAD+ deficiency on a niacin-free diet.
The results show that ANDY mice with ACMSD overexpression
depend on dietary niacin intake and that their NAD+ levels are
tunable by defined diets, ranging from mildly to severely defi-
cient. Our findings suggest that ANDY mice are a powerful
and versatile model for a range of investigations into the links
between NAD+ levels and aging-related diseases, DNA repair,
metabolic disease, as well as for dietary research.
RESULTS
Generation of Mice with Inducible Overexpression of
hACMSD
The ANDY mouse model permits doxycycline (DOX)-inducible
expression of human ACMSD to allow for precise control of
transgeneexpression levels (FigureS1A).ANDYmiceweregener-Cell Repoated using mouse embryonic stem cells
harboring a single copy of the human
ACMSD coding sequence under control
of the tetracycline operator (TetO)
in safe-haven chromatin downstream of
the Col1a1 locus, along with a copy of
M2 reverse tetracycline transactivator(M2rtTA) constitutively expressed from the ROSA26 locus. DOX
in drinking water elicits robust, dose-dependent gene activation
in vivo (Beard et al., 2006). The resulting ANDY mice (C57BL/6J-
Gt[Rosa]26Sortm1[rTTa*M2]JaeCol1a1tm6[tetO-ACMSD]MMF) showed
normal fertility and development, were born in normal Mendelian
ratios, and exhibited no discernible phenotype in the absence
of DOX.
DOX Administration Induces Robust, Sustained
hACMSD Overexpression
Administration of DOX induced hACMSD expression from the
transgene within 48 hr (Figure S1B). As long as DOXwas adminis-
tered,expressionwasmaintained,with4monthsbeing the longest
time interval tested (Figure 2A). In addition, transgene expression
levels depended on hemi- or homozygosity of the hACMSD
and M2rtTA transgenes. ACMSD amounts were highest in ANDYrts 25, 1359–1370, October 30, 2018 1361
mice homozygous for both transgenes, while hemizygosity of
either the hACMSD orM2rtTA alleles (or both) resulted in reduced
levels (FigureS2A). All subsequent investigationsusedANDYmice
homozygous at both the hACMSD andM2rtTA loci.
Acquired Niacin Dependency in Mice with hACMSD
Overexpression
To evaluate dietary niacin requirements for maintaining blood
NAD+ levels, male ANDY mice were kept on either a niacin-free
diet (ND1) or the same diet supplemented with 30 mg/kg niacin
(CD1), or regular chow. Combining these diets with DOX-induced
transgene expression or water-only controls resulted in six
different treatment groups (ANDY/DOX/ND1, ANDY/DOX/CD1,
ANDY/DOX/chow, ANDY/water/ND1, ANDY/water/CD1, ANDY/
water/chow;Figure2B).Animals lacking theM2rtTA transactivator
necessary for ACMSDexpressiononND1andCD1diets provided
additional controls. After 3 weeks on the experimental diets,
blood NAD+ contents were significantly decreased in hACMSD-
expressing ANDY mice on a ND1 (ANDY/DOX/ND1) relative to
ANDY animals on the niacin-replete diet CD1 (ANDY/DOX/CD1)
(Figure 2C). Additional controls at the 4-month point showed
that the decreased NAD+ status depended on the combination
of ND1 and hACMSD overexpression. NAD+ levels in animals on
a niacin-replete control diet (CD1) or regular chow or in animals
that did not overexpress hACMSD due to the absence of DOX or
the M2rtTA were not significantly affected (Figure 2D). Of note,
NAD+ values were significantly reduced in the blood and tissues
of niacin-deficient ND1-fed animals that overexpress hACMSD
(+DOX) compared to ND1-fed ANDY mice not overexpressing
hACMSD (water, DOX) (Figures 2D and S2B). NAD+ phosphate
(NADP+) remained stable until 3 weeks on a niacin-deficient diet
(Figure S2C), but mice on an ND1 diet ultimately became NADP+
deficient as well (Figure S2D). In line with the reduced blood
NAD+ contents, NAD+ was also reduced in liver, kidney, spleen,
and brain of ANDY mice on ND1 diet (Figure 2E). NADP+ values
were also lower in these tissues, but differences were only signif-
icant in liver, blood, and brain, and not kidney and spleen. Blood
NAD+ values decreased similarly in both male and female ANDY
mice on a niacin-deficient diet (Figures S3A and S3B).
The data indicate that in the absence of hACMSD overexpres-
sion, mice do not becomeNAD+ deficient on an ND1, suggesting
that rodents efficiently metabolize tryptophan to NAD+ via the
de novo pathway. In contrast, elevated expression of hACMSD
in the ANDY mice resulted in a dependency on dietary niacin
for the synthesis of NAD+. hACMSD overexpression alone did
not cause NAD+ deficiency in animals on the niacin-replete
CD1 diet or regular chow. Results from ANDY mice and from
controls lacking the M2rtTA allele provide evidence that neither
M2rtTA expression nor DOX administration alone affect NAD+
levels in the absence of the hACMSD transgene. These data
support the hypothesis that elevated expression of hACMSD
results in the dependency of animals on dietary niacin to main-
tain normal NAD+ and NADP+ levels.
NAD+/NADH and NADP+/NADPH Deficiency in ANDY
Mice Is Reversible
To determine the kinetics of declining NAD+ and NADP+ levels
and the reversibility of the observed NAD+ deficiency, we moni-1362 Cell Reports 25, 1359–1370, October 30, 2018tored blood NAD+/NADH and NADP+/NADPH levels over
time in ANDY/DOX/ND1 and ANDY/DOX/CD1 mice. Total blood
NAD+ andNADP+were both significantly lower after 6weeks and
after 16 weeks on ND1 (Figures 3A and 3B). ND1-fed animals
were then put on the niacin-replete CD1 diet. Two weeks after
switching NAD+-deficient mice to the niacin-replete CD1 diet,
blood NAD+ and NADP+ values had recovered and became
indistinguishable from animals continuously fed the CD1 diet
for 18 weeks. Animals on the CD1 diet also had a mild but repro-
ducible and significant decline in blood total NAD+ and NADH
during the 16-week course of the feeding trials, which may be
due to a natural age-related decline in NAD+, similar to what
has been described in humans (Braidy et al., 2011; Zhu et al.,
2015) (Figures S4A and S4B), to adaptation to the diets, or to
the development of the mice.
Declines in both nucleotide pools in ANDY/DOX/ND1 mice
call into question whether the ratio between NAD+ and NADP+
or the total NAD+/NADH pool alone is the most sensitive indica-
tor of niacin deficiency. In clinical use, the ratio has the important
advantage of being independent of sample size. The decline in
blood total NADP+ was less pronounced than the concomitant
lowering of total NAD+/NADH, but statistically significant. These
data support the notion that blood NADP+ levels are more tightly
controlled and fluctuate less than NAD+ levels (Fu et al., 1989),
and they may indicate that NAD+ depletion in the ANDY/DOX/
ND1 groups was severe. In ANDY/DOX/ND1 mice, overall niacin
indices were reduced to <50% of controls, which would be
considered severe in humans (Figures S2D and S2E).
To determine the extent to which tryptophan-to-niacin
conversion is decreased in the ANDY model, a second diet
(ND2) was formulated with 20% casein (twice the tryptophan
of ND1). A niacin-replete diet with matched casein content
served as a second control (CD2) (Table S2). Blood NAD+ levels
in ANDY/DOX animals on ND2 (ANDY/DOX/ND2) for 12 weeks
were lower than NAD+ levels in animals on either niacin-replete
control diet (ANDY/DOX/CD2 and ANDY/DOX/CD1), but less
reduced than in ANDY/DOX/ND1 (Figure 3C), which shows that
ANDY/DOX mice are still able to convert a small proportion of
tryptophan to NAD+.
In summary, the data indicate that the reduced blood NAD+/
NADH and NADP+/NADPH levels in hACMSD-overexpressing
mice lacking dietary niacin return to normal upon dietary niacin
intake. The data also provide evidence that limiting de novo
NAD+ synthesis from dietary tryptophan via the kynurenine
pathway further exacerbates the NAD+ and NADP+ deficiencies
caused by dietary niacin restriction. Thus, diets with defined
niacin and tryptophan content can be used to reduce blood
NAD+ in ANDY mice to defined levels, ranging from mild defi-
ciency on the ND2 diet to severe deficiency on the ND1 diet.
hACMSD Overexpression Results in Elevated
Acetyl-CoA Levels
Hepatic acetyl-CoA levels were significantly increased in all
animals with induced hACMSD expression, regardless of diet
(ND1, CD1, or chow diet) (Figure 4A), suggesting that a signifi-
cant portion of acetyl-CoA may have been generated by trypto-
phan metabolism, but much of the acetyl-CoA could also stem
from sources other than tryptophan. ANDY/DOX mice receiving
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Switch to CD1 Figure 3. NAD+ Deficiency in Animals with
hACMSD Expression Depends on Niacin
and Protein Content in the Diet and Is
Reversible
(A and B) Blood NAD+ (A) and NADP+ (B) levels
declined over time in male ANDY/DOX/ND1
mice, but not in ANDY/DOX/CD1 mice. NAD+ and
NADP+ adjusted to control levels within 2 weeks
after switching NAD+-deficient ANDY/DOX/
ND1 animals to niacin-replete CD1; n = 11 mice
per group. Significance was tested by multiple
t tests with Benjamini two-stage linear step-up
(Tables S3 and S4).
(C) Blood NAD+ levels of male ANDY/DOX mice
depended on the niacin and protein content in
the diets that the animals received for 12 weeks
(Tables S1 and S2). Blood NAD+ content was
lowest in ANDY/DOX/ND1 on the niacin-free, low-
protein diet (ND1). ANDY/DOX/ND2 (on niacin-
free, but higher protein ND2) had slightly higher
blood NAD+ content. Blood NAD+ values of ANDY/
DOX/CD1 and ANDY/DOX/CD2 (on diets with low
protein and 30 mg/kg niacin [CD1], or high protein
and 60 mg/kg niacin [CD2]) were not significantly
different from values measured in ANDY/water/
CD1 (without hACMSD transgene expression).
Data represent mean ± SEM; one-way ANOVA
and Tukey’s multiple comparison test; n = 6–10
per group.
See also Figure S4.standard chow had the highest acetyl-CoA levels, which may
be explained by the higher casein, and therefore tryptophan,
content in chow (20% instead of 10% in the CD1 and ND1 diets;
Table S2). On average, hACMSD overexpression caused a 50%
increase in liver acetyl-CoA (Figure 4B).
Altered NAD+/NADH Ratio and Redox State in
NAD+-Deficient ANDY Mice
As a coenzyme, NAD+/NADH is involved in redox reactions in
which NAD+ is the oxidizing form and NADH is the reducing
form. The total NAD+/NADH ratio is estimated to normally range
from 3 to 10 in mammals (Lin and Guarente, 2003), which
is consistent with results obtained from ANDY/DOX/CD1 and
ANDY/DOX/chow controls (Figure 5A). In hACMSD-overex-
pressing ANDY/DOX/ND1, the NAD+/NADH ratio was signifi-
cantly reduced. The low ratio was due to low NAD+ but not
NADH levels, which remained normal (Figure 5A).
NAD+ Deficiency Is Associated with Lower Pyruvate and
Elevated Lactate Levels
A metabolomics approach to characterize standard liver metab-
olites in ANDY and control mice indicated a significantly altered
pyruvate-to-lactate ratio in the ANDY mice. In the presence of
normal levels of the oxidizing coenzyme NAD+, lactate dehydro-
genase activity converts lactate to pyruvate (Figure 5C). We
quantified the ratio of the two metabolites using comparative
gas chromatography-mass spectrometry (GC-MS) analyses of
livers from niacin-deficient ANDY/DOX/ND1 and niacin-replete
ANDY/DOX/CD1 mice. Livers from niacin-deficient animals con-tained significantly less pyruvate than those from CD1-fed ani-
mals (Figure 5D). In addition, niacin-deficient mice had increased
lactate levels compared to CD1 control animals. Taken together,
the data indicate that NAD+ deficiency and the associated shift in
the hepatic NAD+/NADH redox status in ANDY/DOX/ND1 mice
led to a change in the pyruvate-to-lactate balance.
NAD+-Deficient Mice Lose Weight and Become
Lethargic
ANDY/DOX/ND1 mice invariably lost weight during the course
of the 14-week feeding trials (Figure 6A). This effect was more
pronounced in males than in females (Figure S3C), which was
surprising because females experienced a similar degree of total
NAD+ deficiency (Figures S3A and S3B). In contrast to the niacin-
deficient group, mice fed CD1 or regular chow gained between
10% and 25% of their starting body weight during the same
time interval. CD1-fed mice (ANDY/DOX/CD1 and ANDY/water/
CD1) and ANDY/water/ND1 showed a tendency to become
obese, likely due to the proportionally higher carbohydrate con-
tent of CD1 and ND1 diets compared to normal chow (Figures 6A
and 6B). As early as 3 weeks into the feeding trial, body weights
differed significantly between ANDY/DOX/ND1 and ANDY/DOX/
CD1 mice (Figure 6A, *).
Mice on chow had growth curves typical of C57BL/6J
mice (see C57BL/6J growth chart at https://www.jax.org/jax-
mice-and-services/strain-data-sheet-pages/body-weight-chart-
000664) and body weights consistent with animal age. Niacin-
deficient ANDY/DOX/ND1 was the only group with a downward
trajectory of body weight development. Liver tissue fromCell Reports 25, 1359–1370, October 30, 2018 1363
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Figure 4. hACMSDOverexpression Resulted in Elevated Acetyl-CoA
Contents in Liver
(A) Increased liver acetyl-CoA in male ANDY/DOX after 10 days of doxycline
administration (arrow) compared to ANDY/water animals. Acetyl-CoA in-
creases upon hACMSD overexpression on chow, ND1, and CD1. Student’s
t test; n = 4–5 per group.
(B) Acetyl-CoA increases were independent of feed and associated NAD+
status. Data in (A) were thus summarized to compare hACMSD transgene
induction (ANDY/DOX) to controls (ANDY/water), showing that hACMSD
overexpression caused a 1.5-fold acetyl-CoA increase. Student’s t test; n = 13
per group.
**p < 0.01; ns, not significant. All data represent mean ± SD.
See also Figure S3.ANDY/DOX/CD1 mice exhibited histological changes consistent
with obesity (fatty liver), while the livers of NAD+-deficient mice
ANDY/DOX/ND1 were devoid of fat deposits (Figure 6D). MRI
analyses of the body composition of ANDY/DOX mice at the
end of the feeding trial on ND1, CD1, and chow diets showed
a loss of body fat and a minor variation in lean body mass in
NAD+-deficient animals, while mice on CD1 and chow gained
body fat and lean mass (Figure 6C). Of note, all groups started
the feeding trial with animals of comparable body composition
and age distribution. At the termination of each trial, niacin-defi-
cient ANDY/DOX/ND1mice had accumulated lesswhite adipose
tissue (WAT; average epididymal fat pad weight) than ANDY/
DOX/CD1 or ANDY/DOX/chow mice (Figure 6E). WAT weight
did not differ significantly betweenCD1 and chow control groups
despite the fact that CD1 mice tended to become obese. ANDY/
water/ND1 mice without hACMSD transgene expression had1364 Cell Reports 25, 1359–1370, October 30, 2018WAT similar to CD1 mice. We concluded that hACMSD trans-
gene expression and the resulting NAD+ deficiency in ANDY/
DOX/ND1 mice may cause an inability to accumulate body fat.
In addition, ANDY/DOX/ND1 mice had the smallest amounts of
brown interscapular brown adipose tissue (BAT), together with
mice on chow (Figure 6F). ANDY/DOX/CD1 mice had approxi-
mately three times larger BAT pads than ANDY/DOX/mice on
ND1 or chow. BAT amounts in ANDY/water/ND1 (not overex-
pressing hACMSD) were comparable to CD1 mice and were
2.5-fold higher than ANDY/DOX/ND1with transgene expression,
again indicating that a lack of niacin in the diet alone did not
significantly affect fat metabolism unless the mice simulta-
neously overexpressed hACMSD. Changes in calorie intake
could be ruled out as a cause for the body weight changes be-
tween feeding groups over time. Daily calorie intake averaged
12 kcal/day (Figure S3D). Compared to chow (32%), ND1
and CD1 are relatively protein-poor (10%) and carbohydrate-
rich diets (73% versus 54% in chow) with a similar fat content
(16.8% versus 14% in chow). Food intake only decreased as
mice became severely niacin deficient (Figure S3E), presumably
secondary to behavioral changes. Varying degrees of anorexia
are common for micronutrient deficiencies in rodents, which
may be a protective mechanism against a more rapid metabolic
decline with increased feeding on deficient diets. Feed efficiency
in ND1- and CD1-fed animals was initially similar but dropped to
negative values in ANDY/DOX/ND1, when animals had become
NAD deficient after several weeks on the ND1 diet (Figure S3F).
In line with the neurological symptoms (lethargy, apathy, and
depression) seen in NAD+-deficient humans (Kirkland and
Meyer-Ficca, 2018), NAD+-deficient mice became lethargic
and lacked activity. Compared to ANDY/DOX/CD1 mice,
NAD+-deficient ANDY/DOX/ND1 mice trended toward lower ac-
tivity in an open field test, which measures the distance a mouse
travels to avoid being out in the open (Figure 7A). Compared to
control animals, NAD+ deficient mice showed reduced voluntary
ambulatory activity (Figure 7B).
DISCUSSION
The results of this study support the hypotheses that increased
ACMSD activity within the kynurenine pathway causes depen-
dency on dietary niacin intake in amurine gain-of-function model
and that ACMSDactivity is a source of variation between species
and individuals in the efficiency of conversion of tryptophan to
niacin (Ikeda et al., 1965).
The finding that ANDYmice can be rendered NAD+ deficient to
model human NAD+ deficiency is of interest because NAD+ is
both an essential coenzyme for energy metabolism and a co-
substrate for NAD+-consuming enzymes mediating posttransla-
tional protein modifications, such as sirtuins and ADP-ribose
transferases (Imai and Guarente, 2014). Due to these varied
functions, cellular NAD+may link nutritional status andmetabolic
processes with the activity of epigenetic modulators. In addition,
NAD+-dependent enzymes are involved in various human dis-
eases (e.g., cancer, neurodegeneration, multiple sclerosis,
Alzheimer disease, Huntington disease) and in aging and
longevity. This makes NAD+ metabolism an attractive target for
































Figure 5. Niacin Deficiency in ANDY Mice
Shifted Blood NAD+ to NADH/H+ Ratio
(A) Ratio of oxidized NAD+ to reduced NADH in
males on indicated feed group for 8–12 weeks.
(B) Oxidized NAD+ content was lower inmale ANDY/
DOX/ND1 animals, while NADH values were un-
changed. One-way ANOVA and Tukey’s multiple
comparison test, n = 7 mice per group.
(C) The equilibrium of pyruvate and lactate con-
centrations depends on the NAD+ to NADH ratio.
(D) Comparative GC-MS analysis of liver tissues
showed lower pyruvic acid content and increased
lactic acid content in ANDY/DOX/ND1 compared
to ANDY/DOX/CD1. Student’s t test with Welch’s
correction for unequal variance; n = 7–9.
*p < 0.05, ***p < 0.001, ****p < 0.0001; ns, not sig-
nificant. All data represent mean ± SEM.The experimental evidence obtained from ANDY mice
highlights ACMSD as a master regulator at the intersection of
acetyl-CoA and NAD+ metabolism from tryptophan in the kynur-
enine pathway. Expression of the hACMSD transgene in ANDY
mice increased hepatic acetyl-CoA levels by 50%. This suggests
that although several different metabolic pathways form acetyl-
CoA, the conversion from tryptophan may provide a significant
portion of hepatic acetyl-CoA when hACMSD activity is high.
Alternatively, low NAD+ and NADP+ availability may reduce the
flux of metabolic pathways that consume acetyl-CoA, which
could indirectly cause acetyl-CoA accumulation. The exact
mechanisms causing the observed acetyl-CoA increase remain
to be determined. These results are consistent with the
hypothesis that ACMSD is a key enzyme that regulates the alter-
native processing of tryptophan to either NAD+ or acetyl-CoA,
and overexpression of ACMSD results in reduced NAD+ levels
when niacin intake is low.
Elevated hACMSD expression alone did not change NAD+
levels, except in animals fed the niacin-free ND1 diet, but not
in CD1- or chow-fed controls (Figure 2). In addition, there was
no discernible phenotype of hACMSD expression itself in ani-
mals that were NAD+ replete. Due to the absence of well-stan-
dardized methods for picolinate and quinolinate quantification,
those intermediates were not measured. If elevated hACMSD
expression altered picolinate or quinolinate production, then it
did not result in an outward phenotype in the control animals.
Picolinate, unlike quinolinate, has not been clearly identified asCell Repneurotoxic, but instead may have a physi-
ological role in maintaining the balance
between neurotoxic and neuroprotective
kynurenine pathway metabolites (Grant
et al., 2009). No toxic effects of hACMSD
overexpression or of DOX intake were
seen in control animals not fed a niacin-
deficient diet, even with higher tryptophan
uptake in animals on chow with its higher
protein content.
The endogenous modulation of ACMSD
activity can change hepatic NAD+ levels
(Shin et al., 1999). Glucocorticoids andhigh-protein diets naturally upregulate ACMSD enzyme activity
in wild-type rodents, and polyunsaturated fatty acids and a
low-protein diet downregulate it (Egashira et al., 2004; Fukuoka
et al., 2002). ACMSD activity appears to be controlled at the tran-
scriptional level. Peroxisome proliferator-activated receptor
alpha (PPARa) negatively regulates transcription of nuclear fac-
tor 4 alpha, which normally maintains ACMSD expression (Shin
et al., 2006). Peroxisome proliferators thus increase hepatic
NAD+ by inhibiting ACMSD expression. In the ANDY mouse,
DOX induces hACMSD overexpression independent of endoge-
nous regulators. Increased hACMSD levels result in the opposite
effect, which is decreased NAD+ formation from tryptophan.
Findings of the present study are therefore consistent with
studies of endogenous ACMSD activity regulation. It has been
shown that tryptophan and total nitrogen intake in mice
increase ACMSD activity to formmostly acetyl-CoA. Mice eating
40%–70%protein had extremely high ACMSD activity, and tryp-
tophan-to-nicotinamide conversion was extremely low (Shibata,
2018). The ANDY mouse may mimic a situation of a high-protein
diet, perhaps exacerbated by high carbohydrate intake, but in
the absence of niacin intake. The resulting tryptophan-to-nico-
tinamide conversion is therefore low.
The ANDY mouse should enable future investigations into the
pathophysiology of NAD+ deficiency because it is a tractable
small rodent model. Rats can temporarily become niacin defi-
cient when kept on a gelatin/casein-based diet low in total pro-
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A Figure 6. Altered Body Weight and Composi-
tion in Male Niacin-Deficient Mice
(A) ANDY/DOX/ND1mice (on niacin-free ND1) had a
significant trend to lose body weight (negative slope
of 1.1 in post-test for linear trend, p < 0.0001).
ANDY/DOX/CD1 (on niacin-replete CD1) and
ANDY/DOX/chow (chow) both had a significant
trend for weight gain (slope +1.1, p < 0.0001, and
slope 0.37, respectively). Without transgene induc-
tion (ANDY/water/ND1 and ANDY/water/CD1), both
niacin-deficient and niacin-replete diets caused
significant weight gain (+1.4 and +1.5). Numbers are
body weight after 40 days on feed, as a percentage
of starting body weight. Repeated-measurements
1-way ANOVA, post-test for linear trend; a repre-
sentative experiment of four is shown; n = 4 per
group. *First significant difference between ANDY/
DOX/ ND1 and other feed groups in individual
t tests.
(B) Representative ANDY/DOX/CD1 and ANDY/
DOX/ND1 animals on CD1 or ND1 for 12 weeks.
(C) Body mass composition, shown as fat and lean
mass, at start (left columns) and end (right) of a
12-week feeding trial. Body fat of ANDY/DOX/
CD1 and ANDY/DOX/chow increased significantly
(p < 0.0001 and p = 0.0037, respectively). ANDY/
DOX/ND1 did not gain any body fat. All feed groups
had small but significant changes in lean body
mass. CD1- and chow-fed mice gained lean mass;
niacin-deficient ND1 mice lost lean mass. Body
composition measured by EchoMRI analyzer;
n = 4–7 per group. Data represent mean ± SD.
(D) H&E staining of liver from ANDY/DOX/CD1 and
ANDY/DOX/ND1 shows hepatic lipid accumulation
(fatty liver) in CD1- but not ND1-fed mice. Grayscale
image; scale bar, 200 mm.
(E) Significantly less epididymal fat in ANDY/DOX/
ND1 compared to controls.
(F) Significantly less interscapular brown fat in
ANDY/DOX/ND1 compared to controls. One-way
ANOVA analyses, Tukey’s multiple comparison
tests.
(E and F) All data represent mean ± SEM.
*p < 0.05, ***p < 0.001, ****p < 0.0001; ns, not
significant.weaning age on. The importance of niacin for genomic stability
and for efficient DNA repair upon exposure to alkylating cyto-
toxic agents was demonstrated in such a model (Boyonoski
et al., 1999; Kirkland, 2012; Rawling et al., 1994; Spronck and
Kirkland, 2002). The NAD+ depletion observed in niacin-deficient
rats led to genomic instability in part because NAD+ is the sub-
strate for poly(ADP-ribose) polymerases PARP1 and PARP2,
which are involved in DNA strand break repair and epigenetic
chromatin regulation. Dietary niacin deficiency in young rats
also reduced levels of cyclic ADP-ribose formed from NAD+ by
CD38 and consequently altered learning (Young et al., 2007).
The transient NAD+ deficiency achievable by such a gelatin-
based diet in rats is limited to a short pre-pubertal period, which
limits the versatility of suchmodels andmakes long-term studies
(e.g., aging-related studies) difficult or impossible (Boyonoski
et al., 1999; Rawling et al., 1994; Young et al., 2007). Further-1366 Cell Reports 25, 1359–1370, October 30, 2018more, rats are less amenable to genetic modification than
mice, and therefore there is a paucity of genetic tools available
in rats. This further highlights the versatility of the ANDY mouse,
which can be crossed to the plethora of widely available
reporter and conditional alleles for the study of NAD+ biology
and metabolism.
Another advantage of increasing ACMSD activity to generate
niacin dependency over a knockout approach, in which enzymes
involved in the kynurenine pathway are deleted, is that it avoids
the accumulation of toxic intermediates such as quinolinic acid.
ACMSD activity depletes ACMS, the intermediate in the kynure-
nine pathway that is directed to NAD+ synthesis and thereby
prevents ACMS accumulation (Fukuoka et al., 2002; Fukuwatari
et al., 2002, 2004). Very low ACMSD activity can cause the
accumulation of ACMS and subsequently of quinolinic acid.
Quinolinic acid is an excitotoxic metabolite that can cause or
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Figure 7. Activity Levels Drop over Time with Progressing Niacin
Deficiency
The physical activity of animals was measured as distance traveled in an open
field test (m/5 min) and as number of ambulatory beam breaks.
(A) ANDY/DOX/ND1 distance traveled dropped significantly over time on diet
compared to ANDY/DOX/CD1. One-way ANOVAwith post-test for linear trend
indicated a significant linear decline of activity (slope of 3.658, p = 0.034) in
NAD+-deficient males compared to controls. Data represent mean ± SEM.
(B) Less locomotion indicated by fewer ambulatory beam breaks in NAD+-
deficient males compared to controls; n = 5 per group; Student’s t test and
1-way ANOVA. Data represent box and whisker blots with Tukey’s whiskers.
*p < 0.05, **p < 0.01.contribute to neurodegenerative processes such as epilepsy,
Huntington disease (Beal et al., 1986; Feldblum et al., 1988),
Parkinson disease (Martı́-Massó et al., 2013), and vulnerability
to suicidal behavior in humans (Brundin et al., 2016). The need
to prevent the accumulation of neurotoxic intermediates such
as quinolinic acid likely caused evolutionary pressures favoring
high ACMSD activity in humans, which in turn increases pellagra
susceptibility. Quinolinic acid ismetabolized by quinolinic acid ri-
bosyltransferase (QPRT) to form nicotinic acid mononucleotide
(NAMN). Transfer of anadenylatemoiety toNAMN formsnicotinic
acid adenine dinucleotide (NaAD). Amidation of the nicotinic acid
moiety in NaAD to nicotinamide (Nam) finally forms NAD+. Be-
sides ACMSD, QPRT therefore represents another rate-limiting
step in the tryptophan-to-NAD+ de novo synthesis pathway.
Ablation of theQprt gene in a mouse model resulted in quinolinic
acid levels that were elevated >20-fold (Shibata, 2015; Terakata
et al., 2012). Several other genetic mouse models aimed at dis-rupting NAD+ synthesis from the kynurenine pathway (Figure 1)
have been generated. Genetic deletion of the hepatic enzyme
tryptophan 2,3-dioxygenase (TDO; Figure 1), which forms N-for-
mylkynurenine from tryptophan as the first and rate-limiting step
of the entire kynurenine pathway, still allowed mice to maintain
adequate NAD+ levels, likely through the activity of indoleamine
2,3-dioxygenase (IDO) activity (Terakata et al., 2013). The activity
of IDO may have been able to compensate for the loss of TDO in
themutantmice, at leastwith respect to themaintenanceofNAD+
synthesis for energy metabolism. A genetic deletion of IDO af-
fects the immune response inmice and a number of physiological
responses (Baban et al., 2004). A second IDO was discovered,
IDO2 (Ball et al., 2007; Metz et al., 2007), and TDO, IDO1, and
IDO2 have common and distinct complex functions (Ball et al.,
2014). The important functions of these three enzymes, besides
the initial metabolism of tryptophan in the kynurenine pathway,
create complex phenotypes in mice with disruptions of these
genes (Ball et al., 2014; Larkin et al., 2016; Too et al., 2016). Simi-
larly, the disruption of nicotinamide phosphoribosyltransferase
(NAMPT), the enzyme that catalyzes the rate-limiting step in the
NAD+ salvage pathway, leads to toxic effects (Zabka et al.,
2015). In summary, the pioneering work of other laboratories
showed either complex phenotypes or the accumulation of toxic
metabolites in mice with gene deletions of enzymes involved in
the kynureninepathway.Moreover, theexisting genetic knockout
models, unlike the ANDYmouse, are not ‘‘tunable,’’ and germline
gene deletions can alter development, making phenotype anal-
ysis in adult mice even more complex. It is likely that the poor
efficiency of tryptophan conversion typical of humans is also
related to high ACMSD expression, potentially as a neuroprotec-
tive mechanism, which would make the ANDY mouse a rodent
model potentially applicable to human metabolism. ANDY mice
showed progressive and reversible blood NAD+ andNADP+ defi-
ciency over time, whichwas highly significant as early as 3weeks
after transgene induction on the ND1 niacin-deficient diet. ANDY
mice lost weight, with concurrent alterations in behavior, which
may at least in part be explained by the NAD+ deficiency. NAD+
is an important coenzyme for the conversion of lactate to pyru-
vate, and the limited availability of NAD+ likely resulted in the
observed altered lactate-to-pyruvate ratio. Because pyruvate is
central to energy metabolism in the citrate cycle, reduced
pyruvate levels may directly contribute to loss of body weight.
In addition, disruption of NAD+ redox homeostasis and concur-
rent mitochondrial dysfunction have been associated with meta-
bolic disorders, as recently reviewed byCantó et al. (2015). NAD+
and acetyl-CoA are both co-substrates for enzymes that modu-
late the epigenome, such as sirtuins, PARPs, and histone acetyl
transferases and other protein acetyl transferases. Changing
either NAD+ levels or the relative availability of those two co-sub-
strates may contribute to the altered epigenetic regulation of
genes involved in the control of body weight and lipid meta-
bolism,which is consistentwithwork byCantó et al. (2009), Feige
et al. (2008), Krishnan et al. (2012), and Verdin (2015). The
observed shift in the NAD+/NADH ratio raises the possibility
that niacin-deficient mice have a lowered oxidizing capacity,
while the stable NADH levels suggest that reducing equivalents
are still available for the electron transport apparatus with similar
efficiency to the niacin-replete state.Cell Reports 25, 1359–1370, October 30, 2018 1367
In conclusion, the inducible ANDY mouse is a rodent model of
dietary niacin dependence comparable to the human situation,
with the potential to create varying NAD+ levels and NAD+ defi-
ciency through dietary means. Phenotypic characterization of
NAD+-deficient mice revealed weight loss, reduced liver pyru-
vate content indicative of low energy metabolism, and behavior
changes, all of which are consistent with reduced whole-body
niacin status. This model should be able to advance research
on a vast array of pathologies associated with low NAD+ meta-
bolism, NAD+-dependent DNA repair processes, carcinogen-
esis, epigenetic mark formation, behavioral changes linked to
niacin deficiency, and other areas, including metabolic disorders
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STAR+METHODSKEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Rabbit anti ACMSD (specific for human and mouse) Novus Biologicals Cat# NBP1-33499; RRID:AB_2223750
Mouse anti ACMSD (specific for human) Abnova Cat# H00130013-A01; RRID: AB_463516
Mouse anti alpha-Tubulin Sigma Aldrich Clone DM1A, Cat# T6199;
RRID:AB_477583
Donkey anti-mouse IgG, labeled with CY3 Jackson ImmunoResearch Cat# 715-165-150; RRID:AB_2340813
Donkey anti rabbit IgG, labeled with AF488 Jackson ImmunoResearch Cat# 711-546-152; RRID:AB_2340619
Chemicals, Peptides, and Recombinant Proteins
Bouin’s solution Sigma Aldrich HT10132
Doxycyline Hyclate Sigma Aldrich D9891
Doxycyline Hyclate Alfa Aesar J6057922
NaOH Sigma Aldrich S5881
H3PO4 BioUltra 79617
HClO4 Sigma Aldrich 77234
KOH EMD Millipore 1.05012
Ethanol Sigma Aldrich E7023
Bicine Sigma Aldrich B3876
Thiazolyl Blue Sigma Aldrich M2128
EDTA Disodium EMD Millipore 324503
Bovine Serum Albumin Sigma Aldrich A7906
Phenazine Ethosulfate Sigma Aldrich P4544
Alcohol Dehydrogenase Sigma Aldrich A3263
Isocitrate Sigma Aldrich I1252
Isocitrate Dehydrogenase Sigma Aldrich I1877
NAD (b-NAD+) Sigma Aldrich N0632
NADP (b-NADP+) Sigma Aldrich N8035
Critical Commercial Assays
Acetyl Coenzyme A Assay Sigma Aldrich MAK039
Experimental Models: Cell Lines
KH2 mouse embryonic stem cell line (RRID:CVCL_C317)
Experimental Models: Organisms/Strains
Mus musculus / C57BL/6J-
Gt(Rosa)26Sortm1(rTTa*M2)JaeCol1a1tm6(tetO-hACMSD)MMF
This Study NA
C57BL/6J Jackson Laboratories Stock No: 000664
Oligonucleotides
ACMSD col/frt A1 (50-GCA CAG CAT TGC GGA CAT GC-30) (Beard et al., 2006) NA
hACMSD col/frt-B (50-CCC TCC ATG TGT GAC CAA GG-30) (Beard et al., 2006) NA
hACMSD col/frt C1 (50-GCA GAA GCG CGG CCG TCT GG-30) (Beard et al., 2006) NA
RoseCreERT2 A (50-AAA GTC GCT CTG AGT TGT TAT-30) (Beard et al., 2006) NA
RoseCreERT2 B (50-GCG AAG AGT TTG TCC TCA ACC-30) (Beard et al., 2006) NA




Open Biosystems NCBI: BC107420, NCBI: 130013,
Clone ID: 4594027
pBS31’RBGPA (Beard et al., 2006) NA
(Continued on next page)
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REAGENT or RESOURCE SOURCE IDENTIFIER
pCAGGS-FlpE (Beard et al., 2006) NA
Software and Algorithms
ImageQuant TL GE Healthcare NA
MassLynx 4.1 software Waters NA
QuanLynx Waters NA
Metaboanalysist 3.0 www.metaboanalyst.ca
Oxymax 5.43 Columbus Instruments http://www.colinst.com/
CLAX Columbus Instruments http://www.colinst.com/
ANY-maze behavior tracking software Stoelting https://www.stoeltingco.com/
anymaze.html
Prism 6.0 and 7.0 GraphPad https://www.graphpad.com/
scientific-software/prism/
Other
Niacin deficient ND1 Envigo TD.140376
Niacin Replete CD1 Envigo TD.140375
Niacin Deficient ND2 Envigo TD.150137
Niacin replete CD2 Envigo TD.150136CONTACT FOR REAGENTS AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Mirella L.
Meyer-Ficca (Mirella.meyer@usu.edu).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
hACMSD Transgenic Mice
A tetracycline-responsive system that has a high amplitude of expression versus background transcription levels (Gossen et al.,
1995; Meyer-Ficca et al., 2004) was selected for inducible expression of the human ACMSD (hACMSD) gene (Suppl. Figure S1).
A cDNA clone (NCBI: BC107420, OpenBiosystems, GE Healthcare Dharmacon, Pittsburgh, PA, USA) encoding the human amino-
carboxymuconate semialdehyde decarboxylase (hACMSD) coding sequence was amplified by PCR, sequence verified by conven-
tional sequencing, and ligated into plasmid pBS31’RBGPA, a plasmid designed for FLPe recombination-based transgenesis (Beard
et al., 2006). The resulting targeting vector contains the hACMSD cDNA under the control of a tetracycline-inducible CMV minimal
promoter region. Co-transfection with plasmid pCAGGS-FlpE into the KH2 ES cell line was used to obtain the stable integration of
a single copy of the transgenic expression cassette into safe-haven chromatin downstream of the Col1a1 locus. The KH2 ES cell
line also contains a single copy of the M2rtTA reverse tetracycline transactivator inserted into and under the transcriptional control
of the ubiquitously expressed ROSA26 locus and allows for dose-dependent tetracycline/DOX-inducible gene expression (Beard
et al., 2006; Casola, 2010). Integration of the transgene was verified by Southern Blotting, PCR and inducible expression of the
transgene in selected cell clones was verified using immunoblotting (Figure S1 b.). Transgenic animals were generated by ES
cell injection into blastocysts. Offspring carrying the hACMSD transgene and the M2rtTA transactivator were identified by
conventional genotyping using the following primers (hACMSD col/frt A1 (50-GCA CAG CAT TGC GGA CAT GC-30), hACMSD
col/frt-B (50-CCC TCC ATG TGT GAC CAA GG-30), hACMSD col/frt C1 (50-GCA GAA GCG CGG CCG TCT GG-30),
RoseCreERT2 A (50-AAA GTC GCT CTG AGT TGT TAT-30), RoseCreERT2 B (50-GCG AAG AGT TTG TCC TCA ACC-30),
RoseCreERT2 C (50-GGA GCG GGA GAA ATG GAT ATG-30). The combination of primers A & B amplifies fragments indicating the
presence of the transgene, the combination A & C amplifies a wild-type allele fragment. Transgenic offspring were backcrossed
to C57BL/6J background (B6; The Jackson Laboratories, Bar Harbor, ME USA), and transgenic animals with the official designation
C57BL/6J-Gt(Rosa)26Sortm1(rTTa*M2)JaeCol1a1tm6(tetO-hACMSD)MMF were maintained on a C57BL/6J background. All animals were
maintained and experimental procedures were approved by Institutional Animal Care and Use Committees (IACUC) of Utah State
University and of the University of Pennsylvania. Mice were bred and housed under standard housing conditions (group housing
up to 5 mice per cage). For feeding trials, equal number of age and weight matched were randomly assigned for the experiments
when they were between 7-14 weeks old. Unless indicated otherwise, male mice were used.e2 Cell Reports 25, 1359–1370.e1–e4, October 30, 2018
METHOD DETAILS
hACMSD Transgene Induction and Feeding Regimens
Administration of DOX (DOX hyclate, Sigma Aldrich and Thermo Fisher Scientific) at 2 mg/ml in the drinking water induced transgene
expression in mice. Animals were young adult mice ranging from 7-16 weeks of age with no differences in average age and body
weight between the test groups at the beginning of each long-term feeding trials. Drinking water was changed every 48 hours.
48 hours after starting DOX application, animals were switched from chow to defined diets (see below, and Tables S1 and S2).
Feed consumption was recorded three times weekly in 2-3 day intervals. Feed efficiency was calculated at gram of body weight
gain per consumed calories and day.
Mouse feed composition
Standard chow diet was Teklad Rodent diet 8604 (24% crude protein, 63 mg/kg niacin, Envigo, Madison, WI, USA). Niacin-deficient
diet (ND1) and control diet (CD1) were defined, purified diets that were specially compounded by Teklad laboratory animal diets
(Envigo) as modifications of AIN-93G standard chow. Both, ND1 and CD1 contained 10% alcohol-washed casein as a vitamin-
free protein source to limit tryptophan and niacin and were either supplemented with 30 mg/kg niacin (CD1) or without niacin sup-
plementation (niacin-deficient, ND1). Detailed feed composition in Table S2. Feed intake was determined every 2-3 days by weighing
feed added and leftover feed.
Development of Body Weight and Body Composition
Body weights were recorded three times per week (every 2-3 days). Body composition (body fat, leanmass, water) of each individual
mouse in feeding trials was non-invasively analyzed using an MRI scanner (EchoMRI, Houston, USA) in biweekly intervals.
Open field test
Male mice were placed into an open field (40 cm2) for 5 minutes. A camera captured all horizontal movement and measured freezing.
Movement through various pre-defined zones was analyzed automatically by the Any-maze software.
Locomotion test
Male mice were housed in Columbus Instruments’ Comprehensive Lab Animal Monitoring Systemwith a home cage implementation
(CLAMS-HC). After 3 hours of adjustment, ambulatory activity was measured as counts of break of neighboring infrared beams per
measurement interval of 10 minutes for the duration of 24 hours. Any repeated interruptions of the same infrared beam was not
scored as ambulatory counts. Activity data from CLAMS-HC were sub-grouped into light or dark periods and were analyzed with
the CLAMS data eXamination Tool (CLAX;Columbus Instruments, Columbus OH). Results were shown for the measurements taken
during the dark phase, which represents the active phase in nocturnal animals like mice.
Blood and Tissue Collection, Histology
For repeated-measurements at different time points, 50 mL aliquots of blood were obtained by facial vein puncture using 4 mm or
5 mm lancets (dependent on the age of the animal, Goldenrod, Medipoint), blood was heparinized, snap frozen on dry ice and stored
at80Cuntil further processing. At termination of the study, animals were euthanized, cardiac bloodwas collected and heparinized.
Blood aliquots were snap frozen. Tissues were collected rapidly and snap frozen in liquid nitrogen and stored at 80C. Tissues for
histological analyses were fixed in Bouin’s solution, paraffin embedded and sectioned. Fresh tissue weights were determined for
testes, perigonadal white adipose tissue and interscapular brown adipose tissue.
Immunoblot Analyses
Preparation of tissue lysates was performed as described earlier (Meyer-Ficca et al., 2011). The following antibodies were used:
polyclonal rabbit anti-hACMSD (NBP1-33499, Novus Biologicals, Abnova), monoclonal mouse anti-a-Tubulin (TUBA, clone
DM1A, T90626, Sigma-Aldrich). Secondary antibodies were donkey anti-mouse IgG, labeled with CY3 (Cat.-No. 715-165-150,
Jackson ImmunoResearch, West Grove, PA, USA), donkey anti rabbit IgG, labeled with AF488 (Cat.-No. 711-546-152, Jackson
ImmunoResearch). Fluorescence signals were captured using a Typhoon Fluorescence Scanner and ImageQuant TL software
(both GE Healthcare).
NAD+ Quantification
Blood and tissue NAD+ was quantified using a method described by (Jacobson and Jacobson, 1997; Shah et al., 1995), using chem-
icals from Sigma, Aldrich (St Louis, MO, USA), and assayed on a SpectraMax Plus 384 plate reader (Molecular Devices, Sunnyvale,
CA, USA). Briefly, 55 ml of heparinized whole blood or 30-40 mg of frozen tissue powder were lysed in exactly 10 volumes of 1 M
NaOH. The pH was adjusted to pH 7.0 immediately with 2 M H3PO4, followed by addition of 11 volumes of 1 M HClO4 and a
10 min incubation step on ice. After a subsequent centrifugation (2000 x g, 5 minutes), 2 volumes of supernatant were mixed with
1 volumes of 1 M KOH, incubated on ice for 10 minutes, centrifuged (850 x g, 10 minutes), and the supernatant was used for imme-
diate NAD+/NADP+ quantification. Alternatively, aliquots of the supernatant were stored at 80C until use. For the NAD+/NADP+
Microplate assay, quadruplets of each sample (50 ml lysate, diluted with 50 ml H2O) were measured in a 96-well plate format. 50 ml
of NAD+ mix (10 M EtOH, 1.2 M bicine, 10 mM thiazolyl Blue, 0.2 M EDTA, 100 mg/ml bovine serum albumine, 40 mM phenazineCell Reports 25, 1359–1370.e1–e4, October 30, 2018 e3
ethosulfate and 1mg/ml alcohol dehydrogenase in 0.1M bicine) or NADP+mix (0.2 M isocitrate, 1 M phosphate buffer pH 6.8, 10mM
thiazolyl blue, 0.2 M MgCl2, 100 mg/ml bovine serum albumine, 40 mM phenazine ethosulfate, 10 mg/ml isocitrate dehydrogenase)
were added to each well to quantify NAD+ or NADP+, respectively. The absorbance at 570 nm was measured immediately after
addition of NAD mix and every 10 minutes for about 1 hour. The increase in absorbance over time was used to calculate concentra-
tions. The niacin number of animals was calculated as a measure of niacin status using the following formula: (NAD+ / [NAD+ +
NADP+]) x 100% (Jacobson, 1993; Jacobson and Jacobson, 1997), and then converted to relative niacin indices by dividing the niacin
number of each sample by the average niacin numbers obtained in control animals on niacin replete diet (CD1).
Metabolomics Analysis
Metabolomics analysis was performed at the Metabolomics Core Facility at the University of Utah.
1. Metabolite Extraction
Liver samples were kept at 80C prior to analysis. Frozen liver samples were transferred to labeled bead tubes and weighed. To
each tube, 450 mL of ice-cold 90%methanol solution containing the internal standards (1 mg of d4-succinic acid and 5 mg of labeled
amino acids (13C, 15N – labeled) mixture) were added. Using anOMNI BeadRuptor, sampleswere homogenized at 6.45MHz for 30 s
and then incubated at 20C for 1 hour. After incubation, samples were centrifuged at 20,000 x g for 5 minutes at 4C and the
supernatant transferred to fresh tubes. Quality controls were generated by collecting and combining 15% volume of each sample
into a single tube. Samples were dried in a Speed-Vac vacuum centrifuge.
2. Gas Chromatography-mass spectrometry (GC-MS) analyses:
GC-MS analyses were performed with aWaters GCT Premier mass spectrometer fitted with an Agilent 6890 gas chromatograph and
a Gerstel MPS2 auto sampler. Dried samples were suspended in 40 mL of 40 mg/mL O-methoxylamine hydrochloride (MOX) in pyr-
idine and incubated for one hour at 30C. To each sample of 25 mL, 40 mL of N-methyl-N-trimethylsilyltrifluoracetamide (MSTFA) was
added automatically and incubated for 1h at 37C with shaking. After incubation, 3 mL of a fatty acid methyl ester standard (FAMES)
solution was added, then 1 mL of the prepared sample was injected to the gas chromatograph inlet in the split mode with the inlet
temperature held at 250C. A 10:1 split ratio was used for analysis. The gas chromatograph had an initial temperature of 95C for
one minute, followed by a 40C/min ramp to 110C and a hold time of 2 minutes. This was followed by a second 5C/min ramp to
250C, a third ramp to 350C, then a final hold time of 3 minutes. A 30 m Phenomex ZB5-5 MSi column with a 5 m long guard column
was employed for chromatographic separation. Helium was used as the carrier gas at 1 mL/min. Due to the high amounts of several
metabolites, all samples were also analyzed once more at a 10-fold dilution. Data was collected using MassLynx 4.1 software
(Waters). Metabolites were identified and their peak area was recorded using QuanLynx. Metabolite identity was established using
a combination of an in house metabolite library developed using pure purchased standards and the commercially available NIST
library. Data were transferred to an Excel spread sheet (Microsoft, Redmond WA), and subsequent analysis was performed using
Metaboanalysist 3.0 software (www.metaboanalyst.ca).
Acetyl Coenzyme A Quantification
Acetyl Coenzyme A was quantified using an Acetyl Coenzyme A Assay kit (Sigma Aldrich) according to the manufacturer’s
instructions.
Histological Sections
Histological sections as well as hematoxylin and eosin staining was performed by the Utah Veterinary Diagnostic Laboratory using
standard methods. Grayscale images were taken on a AX10 scope.A1 microscope (Zeiss) equipped with a computer-controlled
charge coupled device (CCD) black-and-white camera (Zeiss Axiocam).
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical Analysis
Data are presented as means ± SD. Comparisons between two groups were performed by Student’s t tests, and multiple t tests with
Benjamini two-stage linear step up. Comparison between 3 and more groups by one-way ANOVA with Tukey’s multiple comparison
tests or with post-test for linear trend. P values are as follows: * indicates p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. Statistical
parameters used are indicated in each figure legend. Statistical evaluation was performed with Prism GraphPad 6.0 and 7.0 (Graph-
Pad Software, LA Jolla, CA, USA).e4 Cell Reports 25, 1359–1370.e1–e4, October 30, 2018
